Cantor Fitzgerald Commences Coverage on ORIC Pharmaceuticals with Positive OutlookCantor Fitzgerald Commences Coverage on ORIC Pharmaceuticals with Positive Outlook

By: Alex Freidmen

Initiating coverage on ORIC Pharmaceuticals (NASDAQ: ORIC) with an overweight rating, Cantor Fitzgerald singles out the promising potential of the company’s oncology wonder, ORIC-114.

ORIC-114, an oral EGFR/HER2 exon 20 inhibitor in the realm of metastatic cancers, shines bright in Cantor’s eyes, boasting a “high probability of emerging as a best-in-class drug” in the competitive pharmaceutical landscape, supporting the existing valuation.

The investment giant estimates the global addressable market for ORIC-114 exceeds $2.5 billion, excluding the Chinese market potential if tailored for EGFR, HER2, and atypical EGFR cancers. Cantor projects unadjusted peak sales to soar to around $700 million across these three lucrative segments, coupling this forecast with a solid 65% probability of success.

But that’s not all – Cantor Fitzgerald also pins high hopes on ORIC’s prostate cancer therapy in the making, ORIC-944, deeming it as offering a “very attractive” risk/reward proposition.


See also  The Unstoppable Rise of S&P 500: ETF's Astronomical $500 Billion Feat, Nvidia's $2 Trillion Triumph, Broadcom Overtakes Tesla